 Vancomycin
"Vancomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
| Descriptor ID |
D014640
|
| MeSH Number(s) |
D09.400.420.925 D12.644.233.925
|
| Concept/Terms |
AB-Vancomycin- AB-Vancomycin
- curasan Brand of Vancomycin Hydrochloride
Diatracin- Diatracin
- Dista Brand of Vancomycin Hydrochloride
VANCO-cell- VANCO-cell
- cell pharm Brand of Vancomycin Hydrochloride
Vanco-saar- Vanco-saar
- MIP Brand of Vancomycin Hydrochloride
Vancocin- Vancocin
- Eli Lilly Brand of Vancomycin Hydrochloride
- Vancomycin Lilly
- Lilly Brand of Vancomycin Hydrochloride
- Vancocine
- Vancocin HCl
|
Below are MeSH descriptors whose meaning is more general than "Vancomycin".
Below are MeSH descriptors whose meaning is more specific than "Vancomycin".
This graph shows the total number of publications written about "Vancomycin" by people in this website by year, and whether "Vancomycin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1983 | 1 | 0 | 1 | | 1984 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1990 | 1 | 1 | 2 | | 1992 | 1 | 1 | 2 | | 1995 | 4 | 0 | 4 | | 1996 | 1 | 1 | 2 | | 1998 | 6 | 1 | 7 | | 1999 | 4 | 2 | 6 | | 2000 | 1 | 1 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 0 | 1 | 1 | | 2008 | 1 | 1 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 3 | 5 | | 2012 | 1 | 1 | 2 | | 2013 | 4 | 1 | 5 | | 2014 | 3 | 1 | 4 | | 2015 | 1 | 2 | 3 | | 2016 | 4 | 0 | 4 | | 2017 | 0 | 3 | 3 | | 2018 | 3 | 0 | 3 | | 2019 | 3 | 1 | 4 | | 2020 | 2 | 4 | 6 | | 2021 | 1 | 2 | 3 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Vancomycin" by people in Profiles.
-
Chiotos K, Fitzgerald JC, Hayes M, Dashefsky H, Metjian TA, Woods-Hill C, Biedron L, Stinson H, Ku BC, Robbins Tighe S, Weiss SL, Balamuth F, Schriver E, Gerber JS. Improving Vancomycin Stewardship in Critically Ill Children. Pediatrics. 2022 04 01; 149(4).
-
Dumaine AM, Du JY, Parent S, Sturm P, Sponseller P, Glotzbecker MP. Use of Vancomycin Powder in the Surgical Treatment of Early Onset Scoliosis Is Associated With Different Microbiology Cultures After Surgical Site Infection. J Pediatr Orthop. 2021 Oct 01; 41(9):e702-e705.
-
Portney DA, Baker HP, Boyle MM, Barbosa VH, Luu HH. Drug Reaction with Eosinophilia and Systemic Syndrome in Revision Arthroplasty for a Prosthetic Knee Infection: A Case Report. JBJS Case Connect. 2021 05 26; 11(2):e20.00805.
-
Yang K, Hou Y, Zhang Y, Liang H, Sharma A, Zheng W, Wang L, Torres R, Tatebe K, Chmura SJ, Pitroda SP, Gilbert JA, Fu YX, Weichselbaum RR. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 03 01; 218(3).
-
Plate M, van Besien K. Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation. Leuk Lymphoma. 2021 02; 62(2):255-256.
-
Kociolek LK. Moving the Needle on Clostridioides difficile Research in Children: A Major Step Forward but Challenges Remain. Clin Infect Dis. 2020 12 17; 71(10):2589-2591.
-
Shaffer SR, Witt J, Targownik LE, Kao D, Lee C, Smieliauskas F, Rubin DT, Singh H, Bernstein CN. Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection. J Infect. 2020 11; 81(5):758-765.
-
Scardina T, Stach L, Sun S, Kociolek LK, Reuter C, Vogt M, Patel S. Documentation of Indications: Agreement Between Order Entry and Clinical Notes and Effect on Time to Antibiotic Administration. J Pharm Pract. 2022 Feb; 35(1):13-19.
-
Nooromid M, Chen EB, Xiong L, Shapiro K, Jiang Q, Demsas F, Eskandari M, Priyadarshini M, Chang EB, Layden BT, Ho KJ. Microbe-Derived Butyrate and Its Receptor, Free Fatty Acid Receptor 3, But Not Free Fatty Acid Receptor 2, Mitigate Neointimal Hyperplasia Susceptibility After Arterial Injury. J Am Heart Assoc. 2020 07 07; 9(13):e016235.
-
Pais GM, Liu J, Avedissian SN, Hiner D, Xanthos T, Chalkias A, d'Aloja E, Locci E, Gilchrist A, Prozialeck WC, Rhodes NJ, Lodise TP, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH. Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. J Antimicrob Chemother. 2020 05 01; 75(5):1228-1236.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|